ANNX earnings date and last-quarter result: next report 2026-08-13, last quarter beat, P/E -4.29. Updated 2026-07-23.
Annexon (ANNX) Research Hub
Annexon (ANNX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.7 USD (-1.33%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.29, market cap 0.62B. This hub links to the full technical, earnings and options research available for ANNX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.7 USD (-1.33%) |
| 52-week range | 3.36 USD – 6.58 USD |
| Trend regime | Range |
| 14-day RSI | 39.9 (Bearish) |
| Trailing P/E | -4.29 |
| Market cap | 0.62B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for ANNX
Covered Call on ANNX: how it works, illustrative setup around the real 3.7 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ANNX: how it works, illustrative setup around the real 3.7 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ANNX: how it works, illustrative setup around the real 3.7 USD price, max profit/loss, breakeven and when to use it. Educational.
ANNX technical analysis: range, last 3.7 USD, RSI 39.9, 52w range 3.36 USD–6.58 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ANNX in?
Annexon (ANNX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ANNX in an uptrend or downtrend?
As of 2026-10-26, ANNX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ANNX's trailing P/E ratio?
ANNX's trailing P/E is -4.29, with a market cap of 0.62B. See the earnings research page for full valuation detail.
When does ANNX next report earnings?
ANNX is next scheduled to report earnings on 2026-08-13.